Strength Seen in Regulus (RGLS): Stock Soars 103.1% – Tale of the Tape

October 23, 2014 Technicals 0

Zacks

Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares surge over 103% on the day. The move came on solid volume with far more shares changing hands than in a normal session. Favorable early test data of a hepatitis C drug was primarily responsible for the upside. This breaks the recent trend of the company, as the stock is now trading above the past one month’s volatile price range of $6.34 to $7.46.

This biopharmaceutical company has seen no estimate revisions in the last 30 days. The Zacks Consensus Estimate has also remained unchanged over the same time frame. Yesterday’s rally is encouraging though, so make sure to keep a close watch on this firm in the near future.

Regulus currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.

Investors looking for well-positioned stocks in the Med-Drugs industry may also consider Cempra, Inc. (CEMP), Lannett Company, Inc. (LCI) and Mallinckrodt plc (MNK). While Cempra and Lannett Company carry a Zacks Rank #1 (Strong Buy), Mallinckrodt holds the same Zacks Rank as Regulus.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

Be the first to comment

Leave a Reply